Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI

Reuters

06-05

Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI

On June 4, 2025, Hansoh Pharmaceutical Group Co. Ltd. announced that its innovative drug, Aumolertinib Mesilate Tablets (trade name: Aumseqa in the UK), has received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom. This approval marks the first overseas launch of a China-developed EGFR-TKI. Aumseqa is approved as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, as well as for those with EGFR T790M mutation-positive NSCLC. The approval signifies a major milestone for Hansoh Pharma, expanding its global reach and bringing innovative cancer treatment options to more patients worldwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2541023107"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541023107\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2541023107?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541023107","market":"nz","top_or_hot":-1,"title":"Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        On June 4, 2025, Hansoh Pharmaceutical Group Co. Ltd. announced that its innovative drug, Aumolertinib Mesilate Tablets (trade name: Aumseqa in the UK), has received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom. This approval marks the first overseas launch of a China-developed EGFR-TKI. Aumseqa is approved as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, as well as for those with EGFR T790M mutation-positive NSCLC. The approval signifies a major milestone for Hansoh Pharma, expanding its global reach and bringing innovative cancer treatment options to more patients worldwide.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-05 17:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        On June 4, 2025, Hansoh Pharmaceutical Group Co. Ltd. announced that its innovative drug, Aumolertinib Mesilate Tablets (trade name: Aumseqa in the UK), has received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom. This approval marks the first overseas launch of a China-developed EGFR-TKI. Aumseqa is approved as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, as well as for those with EGFR T790M mutation-positive NSCLC. The approval signifies a major milestone for Hansoh Pharma, expanding its global reach and bringing innovative cancer treatment options to more patients worldwide.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL8rFL49:1","article_id":"2541023107","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541023107","pubTimestamp":1749115564,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI. On June 4, 2025, Hansoh Pharmaceutical Group Co. Ltd. announced that its innovative drug, Aumolertinib Mesilate Tablets , has received marketing authorization from the Medicines and Healthcare products Regulatory Agency  of the United Kingdom. This approval marks the first overseas launch of a China-developed EGFR-TKI. Aumseqa is approved as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer  with activating epidermal growth factor receptor  mutations, as well as for those with EGFR T790M mutation-positive NSCLC. The approval signifies a major milestone for Hansoh Pharma, expanding its global reach and bringing innovative cancer treatment options to more patients worldwide.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Whil","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1191":"制药","03692":"翰森制药","BK1589":"北水核心资产"},"translate_title":"翰森制药Aumolertinib获英国MHRA批准用于非小细胞肺癌治疗，标志着中国自主研发的EGFR-TKI首次海外上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI\n    \n\n        On June 4, 2025, Hansoh Pharmaceutical Group Co. Ltd. announced that its innovative drug, Aumolertinib Mesilate Tablets (trade name: Aumseqa in the UK), has received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom. This approval marks the first overseas launch of a China-developed EGFR-TKI. Aumseqa is approved as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, as well as for those with EGFR T790M mutation-positive NSCLC. The approval signifies a major milestone for Hansoh Pharma, expanding its global reach and bringing innovative cancer treatment options to more patients worldwide.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}